We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
Korea Investment Corp
151
Korea Investment Corp
South Korea
$122M +$4.95M +170,116 +4%
MLICM
152
Metropolitan Life Insurance Company (MetLife)
New York
$122M -$4.73M -162,666 -4%
Victory Capital Management
153
Victory Capital Management
Texas
$121M -$13.9M -477,632 -10%
NRECA
154
National Rural Electric Cooperative Association
Virginia
$120M
EAM
155
Edge Asset Management
Washington
$119M -$123M -4,233,909 -51%
BCIM
156
British Columbia Investment Management
British Columbia, Canada
$119M -$6.59M -226,361 -5%
Jennison Associates
157
Jennison Associates
New York
$118M -$147M -5,045,054 -55%
N
158
Nuveen
North Carolina
$118M -$1.7M -58,446 -1%
CRM
159
Cramer Rosenthal McGlynn
Connecticut
$117M -$7.1M -244,030 -6%
NI
160
Numeric Investors
Massachusetts
$113M +$50.3M +1,728,665 +80%
AT
161
Alliance Trust
United Kingdom
$113M
ACI
162
AMP Capital Investors
Australia
$112M +$4.25M +146,004 +4%
Caisse de Depot et Placement du Quebec (CDPQ)
163
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$112M -$9.73M -334,329 -8%
SOMRS
164
State of Michigan Retirement System
Michigan
$112M +$1.96M +67,246 +2%
SC
165
Stralem & Co
New York
$111M -$10.4M -358,985 -9%
SCM
166
Sterling Capital Management
North Carolina
$111M +$4.9M +168,368 +5%
O
167
OrbiMed
New York
$109M -$14M -482,100 -11%
JFL
168
Jarislowsky, Fraser Ltd
Quebec, Canada
$108M -$2.57M -88,394 -2%
KCM
169
Kames Capital Management
United Kingdom
$107M -$12M -411,291 -10%
ASC
170
Atalanta Sosnoff Capital
New York
$104M +$11.8M +405,014 +13%
Comerica Bank
171
Comerica Bank
Texas
$102M -$41.6M -1,430,652 -29%
CA
172
Commerzbank Aktiengesellschaft
Germany
$102M +$1.71M +58,607 +2%
Two Sigma Advisers
173
Two Sigma Advisers
New York
$102M +$22.5M +774,690 +28%
Fidelity International
174
Fidelity International
Bermuda
$101M +$33M +1,133,539 +48%
Fifth Third Bancorp
175
Fifth Third Bancorp
Ohio
$101M -$1.4M -48,246 -1%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.